Pediatric Neuroblastoma: Use of Hypermethylation of Apoptotic Genes as a Prognostic Factor

  • Yania Yañez
  • Elena Grau
  • Adela Cañete
  • Victoria Castel
Part of the Pediatric Cancer book series (PECA, volume 4)


Neuroblastoma, the most common solid extracraneal tumor in childhood, develops from immature or de-differentiated neural-crest derived cells. Prognosis depends on the patient’s age at diagnosis, tumor stage and MYCN oncogene amplification. Several established molecular parameters (DNA content, allelic loss in 1p and 11q and gain of genetic material in 17q) have been introduced as prognostic indicators, however, the molecular basis of NB development and progression remains poorly understood. Epigenetic mechanisms, such as DNA hypermethylation, are important regulators of gene expression and are frequently involved in silencing tumor suppressor genes. A clinically relevant methylation profile in NB has recently been studied using different screening techniques and hypermethylation of apoptotic genes such as caspase-8, have been identified as good prognostic indicators, emphasizing the potential use of epigenetic biomarkers for prognosis purposes.


Methylation Status Aberrant Methylation MYCN Amplification International Neuroblastoma Staging System DCR2 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, Ushijima T (2008) Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 74:50–60PubMedCrossRefGoogle Scholar
  2. Alaminos M, Davalos V, Cheung NKV, Gerald WL, Esteller M (2004) Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 96:1208–1219PubMedCrossRefGoogle Scholar
  3. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM, Children’s Oncology Group (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243–2253PubMedCrossRefGoogle Scholar
  4. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216PubMedCrossRefGoogle Scholar
  5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124PubMedCrossRefGoogle Scholar
  6. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T (2010) High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 107:4323–4328PubMedCrossRefGoogle Scholar
  7. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, Task Force INRG (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289–297PubMedCrossRefGoogle Scholar
  8. Decock A, Ongenaert M, Vandesompele J, Speleman F (2011) Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics 6:962–970PubMedCrossRefGoogle Scholar
  9. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516PubMedCrossRefGoogle Scholar
  10. Espada J, Esteller M (2007) Epigenetic control of nuclear architecture. Cell Mol Life Sci 64:449–457PubMedCrossRefGoogle Scholar
  11. Esteller M (2003) Relevance of DNA methylation in the management of cancer. Lancet Oncol 4:351–358PubMedCrossRefGoogle Scholar
  12. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100:940–949PubMedCrossRefGoogle Scholar
  13. Fulda S, Poremba C, Berwanger B, Häcker S, Eilers M, Christiansen H, Hero B, Debatin KM (2006) Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66:10016–10023PubMedCrossRefGoogle Scholar
  14. Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Amiñoso C, Lopez-Marin I, Anselmo NP, Sarasa JL, Gutierrez M, Casartelli C, Rey JA (2003) Aberrant methylation of multiple genes in neuroblastic tumours. Relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39:1478–1485PubMedCrossRefGoogle Scholar
  15. Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V (2010) Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. J Cancer Res Clin Oncol 136:1415–1421PubMedCrossRefGoogle Scholar
  16. Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V (2011) Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 50:153–162PubMedCrossRefGoogle Scholar
  17. Laird PW (2003) The power and promise of DNA methylation markers. Nat Rev Cancer 3:253–266PubMedCrossRefGoogle Scholar
  18. Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío IJ, Castresana JS (2007) Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 174:1–8PubMedCrossRefGoogle Scholar
  19. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL (2005) Evidence for an age cut-off greater than 365 days for neuroblastoma Risk group stratification in the children’s oncology group. J Clin Oncol 23:6495–6465CrossRefGoogle Scholar
  20. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369:2106–2120PubMedCrossRefGoogle Scholar
  21. Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC (2008) Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 50:29–32PubMedCrossRefGoogle Scholar
  22. Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A, Eggert A, Laureys G, Vandesompele J, Speleman F (2008) CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer 8:173PubMedCrossRefGoogle Scholar
  23. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, Hosoi H (2009) RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 100:399–404PubMedCrossRefGoogle Scholar
  24. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, Task Force INRG (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27:298–303PubMedCrossRefGoogle Scholar
  25. Park YJ, Claus R, Weichenhan D, Plass C (2011) Genome-wide epigenetic modifications in cancer. Prog Drug Res 67:25–49PubMedGoogle Scholar
  26. Pritchard J, Hickman J (1994) Why does stage 4s neuroblastoma regress spontaneously? Lancet 344:869–870PubMedCrossRefGoogle Scholar
  27. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372PubMedCrossRefGoogle Scholar
  28. Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, Suzuki M, Shigematsu H, Takahashi T, Parikh G, Pass HI, Chaudhary PM, Gazdar AF (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109:786–792PubMedCrossRefGoogle Scholar
  29. Tang XX, Robinson ME, Riceberg JS, Kim DY, Kung B, Titus TB, Hayashi S, Flake AW, Carpentieri D, Ikegaki N (2004) Favourable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 10:5837–5844PubMedCrossRefGoogle Scholar
  30. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behem FG, Look TA, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 6:529–535PubMedCrossRefGoogle Scholar
  31. van Noesel MM, van Bezouw S, Salomons GS, Voûte PA, Pieters R, Baylin SB, Herman JG, Versteeg R (2002) Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 62:2157–2161PubMedGoogle Scholar
  32. van Noesel MM, van Bezouw S, Voute PA, Herman JG, Pieters R, Versteeg R (2003) Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 38:226–233PubMedCrossRefGoogle Scholar
  33. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM (2005) Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24:2684–2694PubMedCrossRefGoogle Scholar
  34. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T, Misawa-Furihata A, Sugimoto T, Sawada T, Hosoi H (2008) Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 14:7011–7019PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Yania Yañez
    • 1
  • Elena Grau
    • 1
  • Adela Cañete
    • 2
  • Victoria Castel
    • 3
  1. 1.Pediatric OncologyHospital Universitari i Politècnic La FeValenciaSpain
  2. 2.Pediatric OncologyHospital Universitari i Politècnic La FeValenciaSpain
  3. 3.Pediatric OncologyHospital Universitari i Politècnic La FeValenciaSpain

Personalised recommendations